The Neuropathy Case That Ended a Supplement Company

what did the ftc allege about neupathic specifically?

The FTC alleged that Neupathic, one of four dietary supplements named in a November 2020 complaint against Health Research Laboratories, LLC, was marketed with the claim that it 'cures, mitigates, or treats diabetic neuropathy.' The complaint said the company had no adequate substantiation behind that claim. HRL, its sister company Whole Body Supplements, LLC, and owner Kramer Duhon were all named as respondents, and the matter proceeded as an FTC administrative action — Docket 9397 — rather than a federal district court suit.

Diabetic neuropathy is a disease. A cure claim needs real trial evidence behind it, not a testimonial.

The other three products in the same complaint carried cardiovascular claims, not nerve claims — Ultimate Heart Formula, BG18, and Black Garlic Botanicals. Neupathic was the disease-specific outlier, and separating FTC's theory here from FDA's own framework matters: as we've laid out in FDA rules the label, FTC rules your ad, FTC doesn't sort claims into structure/function versus disease categories. It asks only whether you had competent and reliable scientific evidence before you made the claim, full stop.

why was the remedy an industry ban rather than a claim restriction?

The remedy was a full industry ban because Health Research Laboratories was already a repeat violator when the Neupathic claim surfaced, not because a diabetic-neuropathy claim alone forces that outcome. Per FTC's press release announcing the proposed order, the Decision and Final Order, entered June 30, 2022, bars HRL, Whole Body Supplements, and Kramer Duhon personally from advertising or selling any dietary supplement, and separately bars them from claiming any product treats, cures, or reduces the risk of disease.

Put next to comparable nerve- and disease-claim cases — including the Willow Curve refund announcement — the ban stands out as the harshest available remedy; most settlements land on redress plus a narrower claim restriction:

Here's the assumption worth challenging: most people pricing risk into a health-claim offer treat the worst case as a settlement plus a redress check, something you can model into unit economics before you launch. The FTC's own record doesn't support that as a ceiling. Willow Curve's device made nearly the same claim set as Neupathic — diabetic neuropathy, nerve damage, rheumatoid arthritis — and the company kept operating under a $22 million suspended judgment. Health Research Laboratories made a narrower claim on one of four products and lost the right to sell supplements at all. The variable that moved the outcome wasn't the claim's severity; it was whether the company had already broken a promise to the agency once before.

For the mechanics of how FTC actually prices and distributes a redress check, see $3.5M in Refunds at $33 a Check: The Redress Math — that's the more common outcome, and it's not what happened here.

what role did the earlier maine settlement and the contempt motion play?

The earlier settlement and the failed contempt motion are why the case escalated to a ban instead of a first-time claim restriction. Before the Neupathic complaint, HRL and Duhon had already settled prior claims with the FTC and the Maine Attorney General. When new health claims surfaced, the FTC's first move wasn't a new complaint — it moved for contempt, arguing the company had violated that existing agreement.

A federal judge disagreed. Contempt needs a clear violation on the record, and the judge didn't find one.

So the FTC pivoted. It filed the November 2020 administrative complaint that became this case, and it's a reasonable read that the failed contempt motion — a loss for the agency — is part of what pushed the case toward the harshest remedy on the table the second time. We couldn't verify the agency's internal rationale for that escalation; the complaint counsel's charging memo isn't public, and reading it is the only way to settle the question directly.

how do the $46,517-per-violation civil penalties attach?

The $46,517-per-violation figure attaches only if HRL or Duhon violate the final order itself — not for the original Neupathic claim, which the order already resolved. That was the maximum civil penalty per violation of an FTC order at the time the order was entered, June 30, 2022, under the inflation-adjusted cap the Commission publishes. Each sale, each ad run, and arguably each day a banned claim stays live can count as a separate violation, so exposure compounds fast.

That cap has moved since. As of the version currently in force, 16 CFR 1.98 sets the maximum civil penalty per violation at $53,088. If you're evaluating an order against an operator today rather than reading about the 2022 case, use the current figure, not the one quoted in the original press release.

why does diabetic neuropathy attract this severity of remedy?

Diabetic neuropathy attracts this severity because it's a diagnosable, serious disease with an FDA doctrine that treats self-treatment as inherently unsafe — a second regulatory track running alongside FTC's substantiation requirement. FDA's own language, quoted in its 2026 warning letter to VasoCorp over the product NeuropAWAY, holds that neuropathy claims describe a condition 'not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner.' That's the sentence that turns a soft nerve-support claim into a misbranding violation, independent of whatever FTC does.

The enforcement volume backs this up. FDA's warning-letter index returns 26 letters mentioning 'neuropathy' and 42 mentioning 'nerve pain' across all product types, though only 7 and 19 of those respectively come from the food and supplement offices rather than pharmacy or device cases. VasoCorp's own marketing claimed the product was 'clinically proven to reduce the overall symptoms of occasional burning, tingling, and numbness by ~76%' — the kind of specific, quantified promise FDA now quotes back as evidence.

Compare that to a condition that isn't a disease at all: gray hair isn't a disease, and the FTC sued anyway over unsubstantiated reversal claims. Substantiation failure alone is enough for FTC. Diabetic neuropathy just stacks a second regulator and a second legal theory — misbranding, not only deception — on top of the same underlying problem.

what does an industry ban do to the affiliates and networks downstream?

An industry ban binds only the named respondents — here, HRL, Whole Body Supplements, and Kramer Duhon personally — not the affiliates, media buyers, or networks who drove traffic to them. Unless the FTC names a downstream party in the same order, that party stays free to operate and could, in principle, move the same claim to a different brand. Nothing in the public case record we reviewed lists an affiliate or agency co-respondent in the Neupathic matter.

That's not universal FTC practice. When the agency wants to reach downstream actors, it does: Cure Encapsulations was FTC's first case built around fake paid reviews on a third-party retail site, reaching the review vendor as well as the brand. Whether HRL's order reached that far isn't something the public case summary answers.

how should an operator read this before taking a nerve offer?

Read this case as a floor, not a ceiling, on what a diabetic-neuropathy or nerve-pain claim can cost you. Before you run a nerve offer, check three things: the brand's prior FTC and state AG history, whether the specific product name shows up in FDA's warning-letter index, and whether the claim cites a self-run study — because citing your own data doesn't inoculate you, it hands the agency a quote.

FDA has already shown what that looks like. It quoted Calroy Health Sciences' own website back at the company in a 2022 warning letter: 'Diabetic Neuropathy Study....Finding: Arterosil improved objective and subjective measures of neuropathy.' Publishing your own trial result doesn't substantiate the claim under FTC's standard — it just gives FDA a citation.

Timelines vary as much as remedies do. Prevagen's case ran seven years before FTC won it; we counted roughly nineteen months from HRL's complaint to its final order once the agency actually filed. Don't assume a case sitting quiet means it's stalled — assume it means the docket hasn't caught up with your ad account yet.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Energy and Fatigue Offers: Market Map and What Can Be Claimed, Immune Support Offers: A Post-Enforcement Market, Mapped, Blood Pressure Offers: Market, Buyer, and the Hypertension Line, Cholesterol Offers: The Statin-Adjacent Niche and Its Rules, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.